Metformin: a modulator of bevacizumab activity in cancer? A case report. by Indraccolo, Stefano et al.
This article was downloaded by: [Universita' di Padova]
On: 05 August 2015, At: 08:01
Publisher: Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: 5 Howick Place,
London, SW1P 1WG
Click for updates
Cancer Biology & Therapy
Publication details, including instructions for authors and subscription information:
http://www.tandfonline.com/loi/kcbt20
Metformin: a modulator of bevacizumab activity in
cancer? A case report
Stefano Indraccoloa, Giovanni Randonb, Elisabetta Zulatoa, Margherita Nardinc, Camillo
Alibertic, Fabio Pomerric, Alessandra Casarinb & Maria Ornella Nicolettob
a Immunology and Molecular Oncology Unit; Istituto Oncologico Veneto-IOV-IRCCS; Padova,
Italy
b Medical Oncology 2 Unit; Istituto Oncologico Veneto-IOV-IRCCS; Padova, Italy
c Radiology Unit; Istituto Oncologico Veneto-IOV-IRCCS; Padova, Italy
Accepted author version posted online: 21 Jan 2015.
To cite this article: Stefano Indraccolo, Giovanni Randon, Elisabetta Zulato, Margherita Nardin, Camillo Aliberti, Fabio
Pomerri, Alessandra Casarin & Maria Ornella Nicoletto (2015) Metformin: a modulator of bevacizumab activity in cancer? A
case report, Cancer Biology & Therapy, 16:2, 210-214
To link to this article:  http://dx.doi.org/10.1080/15384047.2014.1002366
PLEASE SCROLL DOWN FOR ARTICLE
Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in
the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or
warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions
of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select
articles posted to institutional or subject repositories or any other third-party website are without warranty
from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of
merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this
article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The
accuracy of the Content should not be relied upon and should be independently verified with primary sources
of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands,
costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in
connection with, in relation to or arising out of the use of the Content.
 
This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and
use can be found at http://www.tandfonline.com/page/terms-and-conditions
 
It is essential that you check the license status of any given Open and Open Select article to confirm
conditions of access and use.
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Abbreviations: AMPK, AMP-activated protein kinase; CT, computed tomography; EC, endometrial cancer; LKB1, liver kinase B1;
MCT4, monocarboxylate transporter 4; OS, overall survival; PFS, progression free survival; TACE, trans-catheter arterial
chemoembolization; VEGF-A, vascular endothelial growth factor A.
Recurrent type I endometrial cancer (EC) has poor prognosis and demands novel therapeutic approaches. Bevacizumab, a
VEGF-A neutralizing monoclonal antibody, has shown clinical activity in this setting. To our knowledge, however, although
some diabetic cancer patients treated with bevacizumab may also take metformin, whether metformin modulates response
to anti-VEGF therapy has not yet been investigated. Here, we report the case of a patient with advanced EC treated, among
other drugs, with bevacizumab in combination with metformin. The patient affected by relapsed EC G3 type 1, presented in
march 2010 with liver, lungs and mediastinic metastases. After six cycles of paclitaxel and cisplatin she underwent partial
response. Later on, she had disease progression notwithstanding administration of multiple lines of chemotherapy. In march
2013, due to brain metastases with coma, she began steroid therapy with development of secondary diabetes. At this time,
administration of Bevacizumab plus Metformin improved her performance status. CT scans performed in this time window
showed reduced radiologic density of the lung and mediastinic lesions and of liver disease, suggestive of increased tumor
necrosis. Strong 18F-FDG uptake by PET imaging along with high levels of monocarboxylate transporter 4 and lack of liver
kinase B1 expression in liver metastasis, highlighted metabolic features previously associated with response to anti-VEGF
therapy and phenformin in preclinical models. However, clinical beneﬁt was transitory and was followed by rapid and fatal
disease progression. These ﬁndings—albeit limited to a single case—suggest that tumors lacking LKB1 expression and/or
endowed with an highly glycolytic phenotype might develop large necrotic areas following combined treatment with
metformin plus bevacizumab. As metformin is widely used among diabetes patients as well as in ongoing clinical trials in
cancer patients, these results deserve further clinical investigation.
Introduction
Retrospective studies suggested that metformin is associated with
better survival in patients with endometrial cancer (EC). Metformin
- a biguanide widely used for the treatment of type II diabetes - is
currently under investigation for possible therapeutic applications in
cancer patients in combination with chemotherapy.1 In a 10-year
retrospective study, Nevadunsky et al. reported improved overall
survival (OS) in diabetic patients with non-endometrioid EC who
used metformin compared with other groups, including both dia-
betic patients who did not use metformin and EC in non-diabetic
patients.2 On the other hand, Ko et al. conducted a multicentric ret-
rospective study comparing patients suffering from type 2 diabetes
mellitus using or not metformin at time of diagnosis. This study
demonstrated a 1.8 times worse Recurrence-Free Survival in non-
metformin users (95% CI: 1.1–2.9, pD 0.02 ) and 2.3 times worse
OS (95% CI: 1.3–4.2, p D 0.005) but no significant difference in
Time to Recurrence. Metformin was associated with better survival
in all-cause mortality but its impact in cancer-related outcome was
unclear, as overall health status of patients and glycemic control
were not investigated.3 In any case, other studies have shown that
metformin is associated with improved cancer specific survival in
some types of cancer.4
Bevacizumab, a recombinant humanized monoclonal anti-
body which binds and neutralizes all active isoforms of vascular
endothelial growth factor A (VEGF-A) is currently the leading
anti-angiogenic drug for cancer patients. Based on the positive
outcome of several phase III clinical trials, in Europe bevacizu-
mab was approved by the European Medicines Agency for 5
types of metastatic or locally advanced cancer in combination
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with other drugs.5 In recurrent or persistent EC, clinical activity of
bevacizumab was assessed in a phase II trial.6 Bevacizumab was
given as a single drug (15 mg/Kg every 21 days) to patients who
had received one to 2 prior chemotherapic regimens; clinical
response was observed in 7 of 52 patients (13.5 %, 1 CR and 6
PR) and 40.4% patients remained progression free at least 6
months. Progression free survival (PFS) and OS were 4.2 and
10.5 months, respectively.
To our knowledge, although some diabetic cancer patients
treated with bevacizumab may also take metformin, whether met-
formin modulates response to anti-VEGF therapy has not yet
been explored. Here, we report the case of a patient who was diag-
nosed with endometrial cancer and was treated, among other
drugs, with bevacizumab in combination with metformin. As pre-
sented below, we observed an interesting serological and radiologi-
cal response to single agent bevacizumab and metformin. Notably,
when metformin dosage was reduced due to gastro-enteric distur-
bances, rapid and fatal disease progression was observed.
Case Report
Clinical data
In October 2008, a 63-year-old woman underwent laparo-
scopic hysterectomy, bilateral annessiectomy and pelvic lympha-
denectomy at our center for endometrioid adenocarcinoma of
the uterine body. Pathological examination reported a G3
pT1cN0M0 stage, with estrogen receptor positivity 15% and
progesterone receptor positivity 50%. Post-operative follow-up
was complicated by bladder perforation. No further medical
treatment was performed until April 2010, when a planned CT
(CT) scan revealed liver, lung e mediastinal metastases. Hepatic
needle biopsy showed metastasis of endometrial origin: Histo-
logic grading 3, progesterone receptor positivity 90%, Estrogen
Receptor negative. From April to August 2010, the patient
received first line chemotherapy with a platinum-based regimen
(6 cycles, Cumulative Doses: Paclitaxel 1050 mg/m2 - cisplatin
(DDP) 430 mg/m2), achieving partial response according to
RECIST criteria. Hormonal Therapy with Medroxyprogesteron
(320 mg/die) was prescribed after chemotherapy discontinua-
tion. In December 2010, routine CT imaging showed marked
tumor progression in the liver. Hepatic lesions in the right lobe
were promptly treated with laparoscopic wedge resection (6th-
7th segment) and micro-wave thermal ablation (3rd segment).
From February to May 2011, the patient underwent 2nd line
therapy with 4 cycles Pegylated Liposomal Doxorubicin (PLD)
and Carboplatin (JM8) (Cumulative Dose: PLD 140 mg/m2 –
JM8 AUC5 2110 mg); follow-up CT scan in June 2011 revealed
pulmonary progression, stable mediastinal lymphoadenomegaly
and 4 hepatic nodules. In July 2011, the patient began bevacizu-
mab (7.5 mg/Kg) - increased after 3 cycles at 15 mg/kg 4 - along
with Tamoxifen, which was administered until July 2012. In
November 2011 - due to rising CEA and liver progression - she
underwent hepatic trans-catheter arterial chemoembolization
(TACE) with doxorubicin. In July 2012, weekly Paclitaxel-Car-
boplatin therapy 7 was added to Bevacizumab while
discontinuing Tamoxifen, due to multi-organ progression. In
November 2012, following various episodes of sinus tachycardia,
bevacizumab was temporary discontinued, to prevent cardiac
adverse events, which were reported by Aghajanian et al..4
Weekly Taxol-Carboplatin schedule was also stopped in January
2013, due to rising CEA titer. In February 2013 a lung CT scan
showed progression of known pulmonary and mediastinic lesions
and the patient was symptomatic (cough). Gemcitabine-Carbo-
platin (cumulative dose: Gemcitabine 5800 mg/m2 - JM8
100 mg/m2) was given until March 2013 (2 cycles) when a brain
MRI showed 2 metastatic lesions of the frontal lobe, both of
them <2 cm. Bevacizumab was given in combination with ste-
roids as salvage therapy for brain metastasis and the patient expe-
rienced worsening of blood sugar levels. At that time (March
2013) performance status of the patient was poor, coping with
epilepsy episodes and dyspnea (3 ECOG). Moreover, CEA levels
sharply increased, compared to previous measurements (Fig. 1).
To control glycemia, it was initially employed insulin, replaced
since March 2013 by metformin, (850 mg twice a day), along
with 3 cycles of bevacizumab (7.5 mg/Kg - 15 mg/kg). While
receiving bevacizumab and metformin with no other drugs that
could affect cancer progression we observed a full recovery of the
Performance Status (1 ECOG). CT scans performed at the end
of this window of clinical improvement showed reduced radio-
logic density of the lung and mediastinic lesions, as well as of the
hepatic metastasis, compared with previous scans (Fig. 2). The
volume of the lung and hepatic metastasis, however, was not
reduced and new secondary lesions appeared in the liver; more-
over, a moderate increase in biomarkers of liver injury (including
AST, ALT, ALP and gGT) was measured, whereas renal function
was normal. Peri-lesional brain metastases edema was reduced
(not shown). Serum CEA slightly increased, compared to pre-
treatment values (Fig. 1). The patient did exceptionally well for 2
months. At the end of May 2013, however, the patient began
complaining abdominal discomfort (a known side effect of
biguanides) and metformin was partially (850 £ 1) replaced by
insulin therapy, whereas bevacizumab was continued. In June
2013 the patient’s conditions worsened, due to epileptic seizures
and rising hepatocellular injury markers. At the end of June, she
was admitted to hospital with jaundice. Abdomen US showed
massive metastatic infiltration of the liver and eventually the
patient died after a short time.
Molecular features
Recently, preclinical studies disclosed that anti-VEGF therapy
causes marked impairment in ATP and glucose levels into
tumors, showing that highly glycolytic tumors become largely
necrotic following VEGF blockade.8 These findings suggested
that certain metabolic features of tumor cells could modulate
response to anti-angiogenic therapy. To investigate the metabolic
traits of the tumor of this patient, we analyzed by immunohis-
tochemistry (IHC) expression of monocarboxylate transporter 4
(MCT4), a lactate transporter whose expression is associated
with highly glycolytic cells.9 Intriguingly, we found strong
MCT4 expression in the liver metastases (Fig. 3A), suggesting
presence of highly glycolytic tumor cells. In keeping with these
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findings, strong 18F-FDG uptake was
observed in liver metastasis by PET imaging
(Fig. 3B).
Metformin, a weak inhibitor of respira-
tory complex I, could also cause energy stress
in tumors.1 When combined with anti-
angiogenic therapy, which appears to
increase tumor hypoxia,10 metformin might
further compromise mitochondrial respira-
tion. Although clinical data are lacking, in
pre-clinical models of melanoma metformin
has shown some beneficial effects when com-
bined with anti-VEGF therapy.11 Recently,
increased tumor responses to phenformin - a
biguanide related to metformin - were
reported in non-small cell lung cancer mod-
els bearing genetic inactivation of liver kinase
B1 (LKB1), the major upstream kinase acti-
vating the energy-sensing kinase AMP-acti-
vated protein kinase (AMPK).12 Intrigued by
this study and by our previous observation
linking defects in LKB1/AMPK pathway to
increased tumor necrosis following anti-
VEGF therapy,8 we investigated by IHC
expression of LKB1 in liver metastasis from
this patient. We found that liver metastasis
of this patient lacked LKB1 expression
(Fig. 3A). In contrast, LKB1 was readily
expressed in control tumors that were stained
in parallel (not shown). Loss of LKB1 has
Figure 2. Timeline of morphologic changes in lung and liver metastasis by CT. Representative CT scans of lung (top panels) and liver metastasis (bot-
tom panels) showing marked attenuation of radiologic density following combined administration of bevacizumab plus metformin in a patient with met-
astatic endometrial cancer.
Figure 1. Timeline of drug administrations and CEA levels. Top panel represents the different
drug combinations - including both chemotherapy, bevacizumab and metformin - received by
the patient in 2012–2013. Bottom panel shows serum CEA levels in the same time window.
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also been shown to promote metabolic reprogramming in tumor
cells by an HIF-1a-dependent mechanism,13 suggesting that this
might in part contribute to the highly glycolytic phenotype of
liver metastasis.
These findings - albeit limited to a single case - are in keeping
with results of pre-clinical studies and suggest that lack of LKB1
and an highly glycolytic phenotype might associate with induc-
tion of large necrotic areas following combined treatment with
metformin plus bevacizumab in patients.
Conclusions
In this clinical case, simultaneous administration of metfor-
min and bevacizumab led to increased tumor necrosis at CT scan
and improved performance status in a terminally-ill patient. As
the patient received 2 cycles of gemcitabine plus carboplatin
shortly before beginning bevacizumab plus metformin, a contri-
bution of chemotherapy to this transient clinical benefit cannot
be ruled out. Moreover, it is unclear whether subsequent tumor
progression was due to reduction of metformin dosage or was the
natural course of the cancer. Despite these intrinsic limitations,
this clinical observation suggests that metformin could modulate
bevacizumab activity in highly glycolytic tumors and deserves
further validation in clinical studies.
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